EGFR and Patent ductus arteriosus: Among KRASWT PDA patients, one had SD (50%, no EGFR/HER2/HER3 genomic alterations but positive HER3 protein overexpression by GPS CancerTM proteomic analysis, (NantOmics, Culver City, CA, USA)) and one with HER2-amplified PDA had progressive disease (PD).